MDT

86.58

0%↓

118.81

-1.67%↓

VEEV

169.15

+2.28%↑

HQY

84.25

+1.34%↑

NEOG

9.34

-1.58%↓

MDT

86.58

0%↓

118.81

-1.67%↓

VEEV

169.15

+2.28%↑

HQY

84.25

+1.34%↑

NEOG

9.34

-1.58%↓

MDT

86.58

0%↓

118.81

-1.67%↓

VEEV

169.15

+2.28%↑

HQY

84.25

+1.34%↑

NEOG

9.34

-1.58%↓

MDT

86.58

0%↓

118.81

-1.67%↓

VEEV

169.15

+2.28%↑

HQY

84.25

+1.34%↑

NEOG

9.34

-1.58%↓

MDT

86.58

0%↓

118.81

-1.67%↓

VEEV

169.15

+2.28%↑

HQY

84.25

+1.34%↑

NEOG

9.34

-1.58%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Aperta

35.94 0.22

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

35.39

Massimo

36.42

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+44.69% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	320M 5.9B
Apertura precedente	35.72
Chiusura precedente	35.94

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 apr 2026, 23:14 UTC

Utili

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 apr 2026, 23:14 UTC

Utili

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 apr 2026, 17:13 UTC

I principali Market Mover

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 apr 2026, 23:39 UTC

Discorsi di Mercato

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 apr 2026, 23:35 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 apr 2026, 22:41 UTC

Utili

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 apr 2026, 22:38 UTC

Utili

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 apr 2026, 22:15 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 apr 2026, 22:15 UTC

Discorsi di Mercato

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 apr 2026, 22:14 UTC

Utili

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 apr 2026, 22:12 UTC

Utili

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 apr 2026, 22:11 UTC

Utili

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 apr 2026, 22:11 UTC

Utili

Lens Technology Swings to Loss in 1Q>300433.SZ

15 apr 2026, 22:07 UTC

Utili

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 apr 2026, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 apr 2026, 21:29 UTC

Azioni calde

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 apr 2026, 20:50 UTC

Discorsi di Mercato

Utili

Financial Services Roundup: Market Talk

15 apr 2026, 20:30 UTC

Utili

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

15 apr 2026, 20:06 UTC

Discorsi di Mercato

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 apr 2026, 19:46 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 apr 2026, 19:25 UTC

Discorsi di Mercato

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 apr 2026, 19:00 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 apr 2026, 18:58 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 apr 2026, 18:11 UTC

Acquisizioni, Fusioni, Takeovers

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 apr 2026, 17:45 UTC

Acquisizioni, Fusioni, Takeovers

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 apr 2026, 16:58 UTC

Utili

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 apr 2026, 16:52 UTC

Utili

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 apr 2026, 16:46 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 apr 2026, 16:37 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.69% in crescita

Previsioni per 12 mesi

Media 52.55 USD 44.69%

Alto 64 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.